



## Treating Pediatric Patients With Generalized Myasthenia Gravis?

Consider **referring** your patient to a clinical research study:

“Open-label Uncontrolled Trial to Evaluate Pharmacokinetics, Pharmacodynamics, Safety, and Activity of Efgartigimod in Children From 2 to Less Than 18 Years of Age With Generalized Myasthenia Gravis”

*The investigational study drug, efgartigimod, is not approved by any regulatory agency for use in pediatric patients living with Generalized Myasthenia Gravis as efficacy and safety have not been established.*



or visit [clinicaltrials.gov/study/NCT04833894](https://clinicaltrials.gov/study/NCT04833894) for more information